Vertex Pharmaceuticals Inc


  • US STOCKS-Biotech shares drop, Amarin plunges 20 pct Friday, 12 Sep 2014 | 12:49 PM ET

    NEW YORK, Sept 12- Biotech stocks were among the weakest sectors on Friday, falling as investors continued to take profit in the high-flying sector. Vertex Pharmaceuticals lost 1.2 percent to $93.10 while Amgen was off 0.9 percent to $137.64 and Regeneron Pharma lost 1 percent to $346.82.

  • US STOCKS-Wall St falls, biotech stocks weaker Thursday, 11 Sep 2014 | 1:48 PM ET

    NEW YORK, Sept 11- U.S. stocks were lower on Thursday, with biotechnology shares among the weakest of the day as investors continued to take profits. Celgene Corp was the biggest decliner on the S&P 500, off 3 percent at $91.28, while Vertex Pharmaceuticals was down 2.3 percent at $92.60.

  • S&P 500 hits record on dividend stocks, Ukraine Friday, 5 Sep 2014 | 1:52 AM ET

    The stock market also got a lift from a cease-fire agreement between Ukraine and Russian-backed separatists, aimed at bringing an end to nearly five months of fighting. Stocks had slumped at the beginning of August amid worries that the conflict in Ukraine would spiral out of control and inflame tensions between Russia and the West.

  • NEW YORK, Aug 13- U.S. stocks ended higher on Wednesday, with the Dow Jones industrial average returning to positive territory for the year, as surging biotech shares helped investors shrug off disappointing retail sales data.

  • Macy's Inc quarterly earnings missed analysts' estimates and the department store operator slashed its full-year same-store sales forecast, driving the stock down 5.5 percent to $56.47. Other major retailers, including Wal-Mart Stores Inc, are expected to report results on Thursday. Wal-Mart shares slipped 0.3 percent to $74.03.

  • US STOCKS-Wall Street rises, biotech shares lead rally Wednesday, 13 Aug 2014 | 2:56 PM ET

    NEW YORK, Aug 13- U.S. stocks rose on Wednesday, with the Dow returning to positive territory for the year as the market shrugged off weak earnings reports and a slump in retail shares. Biotech shares surged, with the Nasdaq biotech index climbing 2.1 percent on the back of stocks including InterMune Inc and Jazz Pharmaceuticals PLC.

  • Vertex to end sales of hepatitis C drug Incivek Wednesday, 13 Aug 2014 | 2:42 PM ET

    Aug 13- Vertex Pharmaceuticals Inc is stopping U.S. sales and distribution of its Incivek hepatitis C treatment, whose use has been largely supplanted by the new Sovaldi drug from Gilead Sciences Inc.. Incivek was approved in 2011 and quickly rose to annual sales of more than $1 billion.

  • Aug 1- Express Scripts Holding Co, the largest U.S. pharmacy benefit manager, on Friday said it will remove 25 products from its 2015 list of preferred drugs, including anemia treatments Epogen and Aranesp, both sold by Amgen Inc..

  • NEW YORK, July 28- Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline.

  • This liver disease could rival hepatitis C Tuesday, 15 Jul 2014 | 8:06 AM ET

    The liver disease NASH is becoming more widespread, and the market for treatments may rival those for hepatitis C.

  • 10 stocks on Jim Cramer’s radar, right now Wednesday, 9 Jul 2014 | 6:07 PM ET
    Jim Cramer on Mad Money.

    Uncertain how to put money to work in a market that continues to flirt with all-time highs? Jim Cramer has a few ideas. Ten of them.

  • *S&P 500 pulls back after hitting intraday record. NEW YORK, June 24- U.S. stocks fell on Tuesday as early enthusiasm from economic data faded and concerns about the violence in Iraq gave investors a reason to sell and book some profits, driving the Dow to its biggest drop in over a month. On Tuesday, the Dow suffered its biggest drop since May 20.

  • Check out which companies are making headlines after the bell Tuesday.

  • Dow hit hardest as Iraq concerns overtake US data Tuesday, 24 Jun 2014 | 4:09 PM ET

    Stocks fell, with the S&P 500 turning lower after rising to another record.

  • Look for more upside in these biotech names: Pro Tuesday, 24 Jun 2014 | 2:48 PM ET

    Vertex Pharmaceuticals' spike Tuesday had investors looking for the next breakout stock. UBS's Matt Roden likes these names.

  • NEW YORK, June 24- U.S. stocks turned lower on Tuesday after stronger-than-expected data lifted them to a fresh record earlier in the day, while the sterling tumbled after the Bank of England governor said spare capacity would need to be used up before a rate rise is needed.

  • *S&P 500 pulls back a bit after hitting intraday record. NEW YORK, June 24- U.S. stocks mostly slipped on Tuesday as earlier gains from economic data faded, but the Nasdaq advanced as a result of gains in biotech shares.

  • Stock soars on stunning results on cystic fibrosis Tuesday, 24 Jun 2014 | 12:12 PM ET
    Vertex Pharmaceuticals' headquarters in South Boston.

    A combination of Vertex drugs met the goals of two late-stage clinical trials in cystic fibrosis, setting the stage for Vertex to apply for approval.

  • US STOCKS-Data lift Wall St, S&P hits another record Tuesday, 24 Jun 2014 | 12:00 PM ET

    *S&P 500 hits intraday record, continues recent strength. NEW YORK, June 24- U.S. stocks rose on Tuesday, boosted by some strong data while the Nasdaq outperformed thanks to gains in technology and biotech shares. Consumer confidence hit its highest level since January 2008 in June, while new home sales jumped 18.6 percent to a six-year high in May.

  • Midday movers: DR Horton, Micron, Walgreen & More Tuesday, 24 Jun 2014 | 11:23 AM ET

    Take a look at some of Tuesday's midday movers.